Year Founded
2018
Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Preclinical
Modalities
Frame Pharmaceuticals General Information
Company was acquired by CureVac for their neoantigen platform technology for mRNA cancer vaccines
Drug Pipeline
No pipeline data available
Key Partnerships
CureVac
Frame Pharmaceuticals Funding
Deal Type | Date | Amount | Status | Stage |
---|
To view Frame Pharmaceuticals's complete valuation and funding history, request access »
Frame Pharmaceuticals Investors
Privately funded startup—specific investors undisclosed
Investor Type: Venture Capital
Holding: Minority